Dual-Action Peptide Mazdutide Helped an Obese Teen Lose 17 kg and Reverse Fatty Liver in 36 Weeks

Over 36 weeks of dose-escalated Mazdutide (2 mg → 4 mg → 6 mg weekly subcutaneous injections) combined with metformin and insulin, this 15-year-old patient achieved: 16.8 kg weight loss (18.89% BMI reduction from 30.64 kg/m²), HbA1c reduction of 21.88% (from 9.60%), uric acid decrease of 37.00% (from 511 μmol/L), triglyceride reduction of 69.02%, total cholesterol decrease of 13.65%, LDL cholesterol decrease of 17.27%, and complete resolution of hepatic steatosis by week 14. No hypoglycemic episodes or adverse events occurred, and benefits were sustained after treatment.

This is a single-patient case report. A 15-year-old male with BMI of 30.64 kg/m², HbA1c of 9.60%, and serum uric acid of 511 μmol/L received Mazdutide via subcutaneous injection once weekly, escalating from 2 mg to 4 mg to 6 mg, alongside metformin and insulin. Outcomes were tracked over 36 weeks with blood tests and liver ultrasound imaging.

Mazdutide is a next-generation dual-agonist peptide that targets both GLP-1 and glucagon receptors, potentially offering broader metabolic benefits than GLP-1-only drugs like semaglutide. This is one of the first reports of its use in an adolescent, and the comprehensive metabolic improvements — weight loss, blood sugar control, uric acid reduction, lipid improvement, and fatty liver reversal — suggest it could be particularly valuable for young patients with complex metabolic syndrome.

The peptide therapeutics landscape for obesity and diabetes is expanding beyond single-target GLP-1 agonists. Dual and triple agonists like Mazdutide (GLP-1/glucagon) and tirzepatide (GLP-1/GIP) represent the next wave. This case report adds early evidence that dual agonism may deliver superior metabolic outcomes, and that these benefits extend to adolescents — a population with growing need and limited treatment options.

This is a single case report, which cannot establish causality or generalizability. The patient received Mazdutide alongside metformin and insulin, making it impossible to isolate Mazdutide's individual contribution. No control group or comparison arm exists. Long-term safety in adolescents remains unknown. One patient's experience cannot predict population-level outcomes.